Effect of Lixisenatide in Type 1 Diabetes (LIXI) Study
The LIXI study aimed to determine whether administration of lixisenatide, a Glucagon Like Peptide-1 receptor agonist could improve glycaemic control when added to insulin therapy in people with type 1 diabetes.
Open-label, non-randomised dose-finding pilot stud, followed by a randomised, placebo-controlled, double-blind, cross over trial.
Lixisenatide suppressed glucagon and reduced postprandial glycaemia without compromising counter-regulatory responses during induced hypoglycaemia. The results are currently being submitted for publication.